👍 The FDA board has voted to approve gene therapy for Duchenne muscular dystrophy, which is a positive development in the field of gene therapy.
🔬 The approval shows progress in the regulatory environment for gene therapy and is expected to benefit the gene therapy sector as a whole.
💊 The approval is anticipated to be finalized on May 29th and will have a significant impact on the field of genetic medicine.
💼 The biotech sector has been busy with deal making, with over 70 billion dollars of announced acquisitions so far this year.
🔍 The attractive valuation of small and mid-cap biotech companies has led to increased interest from acquirers.
💰 Capital constraints and limited runway have motivated companies with good technology and prospects to seek acquisitions.
🔍 The approval of gene therapy for Duchenne muscular dystrophy by the FDA board is a significant development.
💰 Commercially successful companies with approved drugs or potential acquisitions tend to have an easier time securing capital.
🎯 Argenx, a later stage company with a successful drug launch, is predicted to be a potential acquisition target.
🧬 The FDA has voted to approve a gene therapy for Duchenne muscular dystrophy.
💼 Blueprint Medicines, a biotech company, is commercializing a drug called Ava kit and has an important upcoming date for an additional indication.
🗓️ An important data for a disease called CIDP is expected to be released in July.
The One A.I. Trick You NEED to Know About...
How To Make Money With eCommerce in 2023 (For Beginners)
Vous Entendrez ces Conseils qu'une Seule Fois dans votre Vie - Earl Nightingale Francais
Interview with new superintendent
Replicon: Multi-Tenant SaaS Solution with Bring Your Own Key (BYOK) Encryption for Enterprises
"AI Could Be The End Of Democracy" - Yuval Noah Harari On The Threat Of Artificial Intelligence